Conversion therapy for advanced penile cancer with tislelizumab combined with chemotherapy: A case report and review of literature

World J Clin Cases. 2022 Nov 26;10(33):12305-12312. doi: 10.12998/wjcc.v10.i33.12305.

Abstract

Background: Locally advanced penile squamous cell carcinoma with unresectable inguinal lymph node metastasis has a poor prognosis, and surgical treatment alone offers limited benefits. Effective conversion therapy regimens are urgently needed.

Case summary: We describe a locally advanced penile squamous cell carcinoma patient with bulky, fixed inguinal lymph node metastasis complicated with genital skin ulcers who underwent inguinal lymph node dissection and achieved a pathological complete response with conversion therapy comprising immunotherapy plus chemotherapy.

Conclusion: For unresectable locally advanced penile squamous cell carcinoma, neoadjuvant immunotherapy combined with chemotherapy is a potential treatment approach. Biomarkers of immunotherapy efficacy need to be explored, and clinical trials are needed to test these strategies.

Keywords: Case report; Conversion therapy; HPV; Immunotherapy; PD-1 blockade; Penile squamous cell carcinoma.

Publication types

  • Case Reports